comparemela.com

Latest Breaking News On - Multiple myeloma clinical research - Page 1 : comparemela.com

Dr Lee on the Rationale for Investigating Linvoseltamab in R/R Multiple Myeloma

Hans Lee, MD, discusses the rationale for the phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory multiple myeloma.

United statesHans leeDepartment of lymphoma myelomaUniversity of texas md anderson cancer centerDivision of cancer medicineMyeloma clinical researchMultiple myeloma clinical researchCancer medicineCancer centerLinker mm1 trialPatients with relapsed refractory multiple myeloma

Dr Lee on the Significance of Longer-Term Data for Linvoseltamab in R/R Multiple Myeloma

Hans C. Lee, MD, discusses the significance of longer-term data for linvoseltamab from the LINKER-MM1 study in relapsed/refractory multiple myeloma.

United statesHansc leeDepartment of lymphoma myelomaMyeloma clinical researchUniversity of texas md anderson cancer centerDivision of cancer medicineMultiple myeloma clinical researchCancer medicineCancer centerThe university of texas md anderson cancer centerOnclive tvMultiple myelomaPhase 2 linker mm1 study nct03761108Bcma cd3 directed bispecific antibody

Linvoseltamab Continues to Elicit Durable Efficacy in High-Risk Relapsed/Refractory Multiple Myeloma

Hans Lee, MD, discusses updated data from the LINKER-MM1 study in heavily pretreated relapsed/refractory multiple myeloma.

United statesHans leeDepartment of lymphoma myelomaAmerican society of hematologyUniversity of texas md anderson cancer centerMyeloma clinical researchRegeneron pharmaceuticals incMultiple myeloma clinical researchCancer centerMultiple myelomaPhase 1 2 linker mm1 study2023 ash annual meetingThe university of texas md anderson cancer center

Linvoseltamab Produces Durable Responses in Relapsed/Refractory Multiple Myeloma

Hans Lee, MD, discusses unmet needs in patients with relapsed/refractory multiple myeloma, highlights key efficacy and safety findings from the LINKER-MM1 trial, and how these data may inform the future of the multiple myeloma treatment paradigm.

United statesHans leeBristol myers squibbDivision of cancer medicineMyeloma clinical researchDepartment of lymphoma myelomaUniversity of texas md anderson cancer centerMultiple myeloma clinical researchCancer medicineCancer centerAllogene therapeuticsKaryopharm therapeuticsLegend biotechMonte rosa therapeuticsMultiple myeloma

Dr Lee on the Investigation of Linvoseltamab in Relapsed/Refractory Multiple Myeloma

Hans C. Lee, MD, discusses the investigation of the BCMA x CD3 bispecific antibody linvoseltamab in patients with relapsed/refractory multiple myeloma.

United statesHansc leeDivision of cancer medicineUniversity of texas md anderson cancer centerDepartment of lymphoma myelomaMyeloma clinical researchMultiple myeloma clinical researchCancer medicineCancer center

vimarsana © 2020. All Rights Reserved.